EPS at Rs 32.19
Substantial reduction in losses
Demand normalisation post the second wave contributed to the steady growth
Income declines marginally
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The company has strong product launches both in India and overseas
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
The American Association for Clinical Chemistry (AACC); the American Society for Clinical Pathology (ASCP); the American Society of Hematology (ASH); and the International Myeloma Working Group (IMWG), collaborate to develop the guideline
Subscribe To Our Newsletter & Stay Updated
